Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907953 · ClinicalTrials.gov registry record
CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases
A clinical trial of Long COVID and Sarcoidosis, sponsored by 4YouandMe.
- Completed
- Registry status
- 239
- Enrollment target
- 1
- Study location
NCT06907953 is a study of Long COVID and Sarcoidosis that has completed, run by 4YouandMe. The registered enrollment target is 239 participants, below the 2,183-participant average among 50 other Long COVID trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06907953, a study of Long COVID and Sarcoidosis, has completed, sponsored by 4YouandMe.
- COMPLETED
- Registry status
- 239 participants
- Enrollment target
- 1
- Study location
Study Summary
The CZI Rare As One study is a Chan Zuckerberg Initiative funded study that aims to co-design and pilot test unique symptom tracking and transmitting apps across 5 different sub-arms that includes individuals with Long COVID, Pancreatitis, Sarcoidosis, Vasolin-Containing Protein (VCP) disease and Primary Ciliary disease (PCD). This study aims to use multimodal digital health tools to enable patients to self-monitor their symptoms in passive and active ways.
Conditions Studied
Interventions
- OTHER Observational - no intervention
Study Locations (1)
New York
- 4YouandMe - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2025-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06907953
The ClinicalTrials.gov registry entry for NCT06907953 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,183-participant average among 50 other Long COVID trials with a reported enrollment target (89% lower). The listed sponsor is 4YouandMe, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Observational - no intervention is the first listed.
NCT06907953 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06907953 about?
NCT06907953 is a clinical study titled "CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases". The CZI Rare As One study is a Chan Zuckerberg Initiative funded study that aims to co-design and pilot test unique symptom tracking and transmitting apps across 5 different sub-arms that includes individuals with Long COVID, Pancreatitis, Sarcoidosis, Vasolin-Containing Protein (VCP) disease and Pr...
What is the current status of trial NCT06907953?
This trial is currently completed. The enrollment target is 239 participants. The study started on 2025-02-06. Estimated completion is 2025-07-01.
What conditions does trial NCT06907953 study?
This clinical trial studies the following conditions: Long COVID, Sarcoidosis, Symptoms and Signs, Pancreatitis, Chronic, Wearables.
What interventions are being tested in trial NCT06907953?
The interventions under investigation include: Observational - no intervention (OTHER).
Who is sponsoring clinical trial NCT06907953?
This trial is sponsored by 4YouandMe, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907953 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Sauna for Long Covid
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.